Corbus' CRB-913 shows 5% mean weight loss at 12 weeks in Phase 1b trial

By Public Technologies
  • Corbus Pharmaceuticals presented Phase 1b CANYON-1 trial results for its oral obesity drug CRB-913 at ObesityWeek 2026.
  • CRB-913 produced statistically significant, clinically meaningful weight loss across all tested doses, with no plateau observed.
  • Psychiatric adverse events were mostly mild and resolved; no serious or severe psychiatric events were reported.
  • Corbus plans FDA discussions on further development and is evaluating potential combinations with GLP-1 therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160800PRIMZONEFULLFEED9878103) on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.